Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab.
Meuth SG, Wolff S, Mück A, Willison A, Kleinschnitz K, Räuber S, Pawlitzki M, Konen FF, Skripuletz T, Grothe M, Ruck T, Huttner HB, Kleinschnitz C, Bopp T, Pul R, Cree BAC, Hartung HP, Möllenhoff K, Pfeuffer S. Meuth SG, et al. Among authors: kleinschnitz k. Ann Neurol. 2024 Nov 25. doi: 10.1002/ana.27143. Online ahead of print. Ann Neurol. 2024. PMID: 39582359
Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab.
Pfeuffer S, Rolfes L, Ingwersen J, Pul R, Kleinschnitz K, Korsen M, Räuber S, Ruck T, Schieferdecker S, Willison AG, Aktas O, Kleinschnitz C, Hartung HP, Kappos L, Meuth SG. Pfeuffer S, et al. Among authors: kleinschnitz k. Neurol Neuroimmunol Neuroinflamm. 2023 Apr 11;10(3):e200104. doi: 10.1212/NXI.0000000000200104. Print 2023 May. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37041077 Free PMC article.
Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study.
Rolfes L, Pfeuffer S, Huntemann N, Schmidt M, Su C, Skuljec J, Aslan D, Hackert J, Kleinschnitz K, Hagenacker T, Pawlitzki M, Ruck T, Kleinschnitz C, Meuth SG, Pul R. Rolfes L, et al. Among authors: kleinschnitz k. Mult Scler Relat Disord. 2022 Aug;64:103931. doi: 10.1016/j.msard.2022.103931. Epub 2022 May 29. Mult Scler Relat Disord. 2022. PMID: 35690010 Free article.
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.
Rolfes L, Pawlitzki M, Pfeuffer S, Nelke C, Lux A, Pul R, Kleinschnitz C, Kleinschnitz K, Rogall R, Pape K, Bittner S, Zipp F, Warnke C, Goereci Y, Schroeter M, Ingwersen J, Aktas O, Klotz L, Ruck T, Wiendl H, Meuth SG. Rolfes L, et al. Among authors: kleinschnitz k. Neurol Neuroimmunol Neuroinflamm. 2021 Jul 14;8(5):e1035. doi: 10.1212/NXI.0000000000001035. Print 2021 Sep. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34261812 Free PMC article.
Cell stress molecules in the skeletal muscle of GNE myopathy.
Fischer C, Kleinschnitz K, Wrede A, Muth I, Kruse N, Nishino I, Schmidt J. Fischer C, et al. Among authors: kleinschnitz k. BMC Neurol. 2013 Mar 12;13:24. doi: 10.1186/1471-2377-13-24. BMC Neurol. 2013. PMID: 23496965 Free PMC article.